id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1464-0016,FDA,FDA-2013-D-1464,"Bioequivalence Studies With 
Pharmacokinetic Endpoints for Drugs 
Submitted Under an Abbreviated New 
Drug Application; Draft Guidance for 
Industry; Availability",Notice,Notice of Availability,2021-08-23T04:00:00Z,2021,8,2021-08-23T04:00:00Z,2021-10-23T03:59:59Z,2021-09-09T01:00:34Z,2021-18073,0,0,0900006484c9bd68
FDA-2013-D-1464-0017,FDA,FDA-2013-D-1464,Bioequivalence Studies With  Pharmacokinetic Endpoints for  Drugs Submitted Under an ANDA Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2021-08-23T04:00:00Z,2021,8,2021-08-23T04:00:00Z,,2021-08-23T15:58:32Z,,0,0,0900006484c9cc0c
FDA-2013-D-1464-0001,FDA,FDA-2013-D-1464,Draft Guidance for Industry on Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Availability,Notice,Notice of Availability,2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,2014-03-06T04:59:59Z,2014-03-06T02:01:21Z,2013-29081,0,0,09000064814a9ea0
FDA-2013-D-1464-0002,FDA,FDA-2013-D-1464,Guidance for Industry; Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA,Other,Guidance,2013-12-04T05:00:00Z,2013,12,2013-12-04T05:00:00Z,,2024-11-12T05:24:47Z,,1,0,09000064814aa14c